Mindray has launched new artificial intelligence (AI)-enabled platelet counting technology in the EU that the company says can reduce the risk of diagnostic error in cancer diagnoses and improve treatment of hematology disorders.
The CAL 8000 Cellular Analysis Line combines platelet technologies and automated platelet analysis. The product incorporates high-precision optics and offers several AI algorithms designed for functions, such as excluding interference, increasing particle counting, and advanced morphological imaging as needed.
The system is designed to mitigate the risk of low platelet count, pseudothrombocytopenia, that can occur during platelet aggregation or due to improper sample handling, or that may arise in samples with large or giant platelets that conventional methods cannot identify, according to the company.
Mindray said accurate platelet count testing is one of the major challenges facing laboratories. Inaccurate counting can lead to misdiagnosis or missed diagnosis, and delayed treatment of conditions such as acute massive hemorrhage, coagulation problems, infections, autoimmune diseases, and cancers.
